Methods of treating cancer using an EZH2 inhibitor and a tricyclic quinolone heterobifunctional degrader of BCL6

A combination therapy using Compound 1001 and Formula (A) targets and degrades BCL6 and inhibits EZH2, addressing the limitations of current treatments for relapsed or refractory B-cell lymphomas, providing effective treatment options for DLBCL, FL, and PTCL.

WO2026128805A1PCT designated stage Publication Date: 2026-06-18TREELINE BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
TREELINE BIOSCIENCES INC
Filing Date
2025-12-12
Publication Date
2026-06-18

Smart Images

  • Figure US2025059389_18062026_PF_FP_ABST
    Figure US2025059389_18062026_PF_FP_ABST
Patent Text Reader

Abstract

This disclosure provides methods for treating cancer and other diseases using Compound 1001, or a pharmaceutically acceptable salt thereof, and a compound of Formula (A) (e.g., Formula (A-1)), Formula (I) (e.g., Formula (I-aa) (e.g., Formula (I-aa-1), (I-aa-2), (I-aa-3), (I-aa-4), (I-aa-5), or (I-aa-6)), Formula (I-a) (e.g., Formula (I-a-1), (I-a-2), (I-a-3), (I-a-4), (I-a-5) or (I-a-6)), or Formula (I-bb) (e.g., Formula (I-bb-1) or (I-bb-2))), or a pharmaceutically acceptable salt thereof. This disclosure also provides compositions containing the same.
Need to check novelty before this filing date? Find Prior Art